|Home | About | Journals | Submit | Contact Us | Français|
To produce a growth reference for British children with Williams syndrome.
The children and adults recruited into the study were all affiliated to the Williams Syndrome Foundation, a parent support group founded in 1979. They have all been shown to have a deletion of chromosome 7q11.23. One growth nurse (WRS) prospectively measured the weight, height and head circumference of individuals from 19 regions in Great Britain including Scotland, England and Wales. 169 children and adults were measured on up to four occasions between 2001 and 2004 (275 measurements). In addition, retrospective data were obtained from the hospital notes of 67 of these individuals (586 measurements). Centile curves were constructed using Cole's LMS method.
The centile charts differ from charts previously derived in the USA and Germany and provide more appropriate standards for the British population.
We propose that these charts be adopted for routine clinical practice as abnormalities in growth are an important feature of this syndrome.
Short stature is a recognised feature of Williams syndrome. This syndrome was first described in 1961 as a triad of supravalvular aortic stenosis, learning difficulties and unusual facial features.1 It was quickly recognised as being linked with infantile hypercalcaemia and in 1993, Ewart et al demonstrated the presence of a micro deletion on chromosome 7 (del 7q11.23) in all children with this syndrome.2,3 To date, 28 genes have been detected within this region, including the elastin gene. The genes responsible for the developmental abnormalities and hypercalcaemia remain to be determined. A number of large cohort studies have described the presence of low birth weight, failure to thrive in infancy, short stature and precocious puberty.4,5,6 In addition to congenital heart disease and infantile hypercalcaemia, children with Williams syndrome have been described as having hypothyroidism,7 growth hormone insufficiency8,9 and coeliac disease.10 These diverse conditions make accurate assessment of growth an essential requirement of health surveillance.
Morris et al produced growth charts for children with Williams syndrome in 1988 from retrospective, cross‐sectional data collected from American children attending either their clinic in Salt Lake City, Utah or a Williams Syndrome National Association meeting in 1986.11 The mean adult heights of males and females were 167 and 157 cm, respectively. Pankau et al published retrospective data from a cohort of German children with Williams syndrome and in this population mean adult heights for males and females were 168 and 154 cm, respectively.12 Both these studies were published before the gene deletion had been identified. Partsch et al subsequently documented a prospective study of a cohort of the same German children in 1999 but again the diagnosis was only confirmed genetically in 44% of cases.6 Mean adult heights for this cohort of males and females were 165 and 152 cm, respectively. The most recent British data were published by Martin et al in 1984 and in that cohort mean adult heights for males and females were 159 and 147 cm, respectively. Therefore, we identified the need for a contemporary British growth reference for children with genetically diagnosed Williams syndrome.4
The study was approved by the South Thames Multicentre Research Ethics Committee and local ethics committees. Individuals were affiliated to the Williams Syndrome Foundation, the UK parent support group (www.williams‐syndrome.org.uk). Written consent was obtained to measure children with Williams syndrome at intervals, obtain blood for chromosome analysis as necessary and review available hospital records.
Adults (age >20 years) were measured once. Children were measured between one and four times between January 2001 and December 2004. A brief medical history was obtained. No individuals had been treated with growth hormone. Five children had been treated with thyroxine, but only three remained on medication. Three individuals had been diagnosed with diabetes mellitus, including two adults with late onset non‐insulin dependent diabetes. Genetic status was confirmed either from the hospital records or from the appropriate cytogenetic laboratory. The methods used were either the Vysis (Abbot Molecular, Des Plaines, IL, USA; ELN‐, LIMK‐, D7S613‐) or Oncor (Gaithersburg, MD, USA; D7S427‐) probe. Where no record was available, consent for blood letting was obtained and samples were analysed in the Academic Unit of Medical Genetics, Manchester using the Vysis probe (M Tassabehji, personal communication).
WS performed all prospective height measurements using a Leicester stadiometer (Crawlea Medical, Birmingham, UK) and the non‐stretch technique. Individuals wearing light clothing and without footwear were electronically weighed using Tanita THD‐305 scales (Tanita, Yiewsley, Middlesex, UK). Head circumferences were measured with the Lasso‐O tape measure (Child Growth Foundation, London, UK). Retrospective data would have been collected using variable techniques with standard child surveillance equipment.
A list of 615 children and adults was obtained from the Williams Syndrome Foundation. A total of 219 children or adults consented to take part in the study. Measurements were obtained and chromosomal deletion confirmed in 169 subjects (86 male and 83 female).
Plots of height, weight and head circumference were used to identify gross errors, which were compared to the original forms and transcription errors corrected. Centile curves were fitted to the data using Cole's LMS method.13 This assumes that the data can be transformed to normality by a suitable power transformation (L) and the distribution is then summarised by the median (M) and coefficient of variation (S). The values of L, M and S are constrained to change smoothly with age and the fitted values can be used to construct centile curves. Centiles were constructed using the nine centile curves as described by Cole.14 Centile lines are placed exactly two thirds of an SD score apart leading to the current 2, 9, 25, 50, 75, 91, 98 pattern.
Table 11 lists the frequencies of measurement by age. Of the 861 measurements, 275 were prospectively collected and the remaining 586 were retrospective. The numbers of measurements by sex (male/female) were as follows: weight 417/394, height 387/354 and head circumference 160/135. Centile charts for female height, weight and head circumference are shown in infigsfigs 1–3. Centile charts for male height, weight and head circumference are superimposed on those of Morris et al in infigsfigs 4–6.11 Centile charts for female and male body mass index (BMI) are shown in infigsfigs 7 and 88.
We have produced the first British growth charts for Williams syndrome and the first charts where the genetic status of all individuals has been confirmed. Mean heights for adult males and females with Williams syndrome were 159 and 152 cm, respectively. Thus, they are on average 18 and 12 cm shorter than reference British adult males and females.15 These mean heights are similar to previous data of Morris et al, but the growth curves are significantly different with, in particular, wider centile ranges for male heights and weights. Head circumferences in both males and females were 1–2 cm greater across all ages from 2 to 18 years.
The short stature in Williams syndrome can be accounted for by (a) restricted growth prenatally, (b) failure to thrive in infancy, (c) restricted growth in childhood and (d) precocious puberty. Kyphoscoliosis may make height measurement difficult and it is unlikely that congenital heart disease restricts growth in most cases.4,11,12 Rarely other diseases have been reported to impair growth and the use of these charts may aid diagnosis and management. Thus, there at are least two published reports of growth hormone insufficiency in association with Williams syndrome.8,9 In addition, the KIGS database, a voluntary database of growth hormone prescribers, identifies 19 cases of Williams syndrome treated with growth hormone between 1986 and 2000 (M Mistry, personal communication). Abnormal thyrotrophin and thyroid hormone secretion has been reported in a number of case reports and dysgenesis of the thyroid gland may be associated with the syndrome.7,16 Premature activation of the hypothalamic‐pituitary‐gonadal axis is now recognised both in this syndrome and other conditions associated with learning difficulties.17,18,19 Finally, a number of authors have suggested that coeliac disease is more common in Williams syndrome, although preliminary data from this study do not confirm these observations.10,20
Concerns were raised by the first British cohort study that obesity might be more prevalent, particularly in adult life.4 Furthermore, obesity has been noted in the knock‐out mouse model for Williams syndrome (M Tassabehji, personal communication). Other authors have described the opposite. Kaplan et al in a small series demonstrated decreased percentage body fat in four out of six individuals studied.21 Pankau et al analysed data from his longitudinal study of growth in Williams syndrome and demonstrated lower BMI in infancy and early childhood in both males and females, increasing in adult life towards the mean.22 He did not detect significant obesity.
Calculating BMI values for both males and females from this cohort and comparing them with current British centile curves23 confirms Pankau's findings that obesity is not prevalent in childhood or adolescence but may develop in adult life. It is likely that activity levels and diet are the main predisposing factors, but other metabolic determinants may be important.21 Whatever the explanation, any tendency to develop obesity and possible insulin resistance with the precedent of prenatal growth restriction would be of concern, particularly given the frequent association of supravalvular aortic stenosis, hypertension and an abnormal vascular tree.24,25 In this cohort 14 individuals were being treated for hypertension and two for type 2 diabetes.
Charts have been produced which are appropriate for British children with Williams syndrome. Growth surveillance throughout childhood will enable coexistent growth disorders to be detected. Guidance on other aspects of health surveillance for children and adults with Williams syndrome is available from the Williams Syndrome Foundation (www.williams‐syndrome.org.uk).
We would like to thank the Williams Syndrome Foundation for funding this project and for the help of all the families involved. We would also like to thank May Tassabehji for genetic testing and advice and John Short and his team at Harlow Printing for steering the final production of the growth charts.
Pharmacia and Pfizer UK provided generous financial support.
Competing interests: None.
Copies of the A4 charts and PCHR inserts are available from Harlow Printing, Maxwell Street, South Shields, Tyne and Weir NE33 4PU, UK or from the Williams Syndrome Foundation.